Macarena I De La Fuente

Assistant Professor of Clinical

  • 208 Citations
20092020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Macarena I De La Fuente is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 7 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Central nervous system emergencies in haematological malignancies

de la Fuente, M. I., Alderuccio, J. P. & Lossos, I. S., Jun 1 2020, In : British Journal of Haematology. 189, 6, p. 1028-1037 10 p.

Research output: Contribution to journalReview article

  • Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

    Smyth, L. M., Piha-Paul, S. A., Won, H. H., Schram, A. M., Saura, C., Loi, S., Lu, J., Shapiro, G. I., Juric, D., Mayer, I. A., Arteaga, C. L., de la Fuente, M. I., Brufksy, A. M., Spanggaard, I., Mau-Sørensen, M., Arnedos, M., Moreno, V., Boni, V., Sohn, J., Schwartzberg, L. S. & 27 others, Gonzàlez-Farré, X., Cervantes, A., Bidard, F. C., Gorelick, A. N., Lanman, R. B., Nagy, R. J., Ulaner, G. A., Chandarlapaty, S., Jhaveri, K., Gavrila, E. I., Zimel, C., Selcuklu, S. D., Melcer, M., Samoila, A., Cai, Y., Scaltriti, M., Mann, G., Xu, F., Eli, L. D., Dujka, M., Lalani, A. S., Bryce, R., Baselga, J., Taylor, B. S., Solit, D. B., Meric-Bernstam, F. & Hyman, D. M., Feb 1 2020, In : Cancer discovery. 10, 2, p. 198-213 16 p.

    Research output: Contribution to journalArticle

    Open Access
  • 5 Scopus citations

    Erdheim-Chester disease among neuroinflammatory syndromes: the case for precision medicine

    de la Fuente, M. I., Rosenblum, M. K., Diamond, E. L., Tabar, V. S. & Omuro, A., May 1 2020, In : Neurology(R) neuroimmunology & neuroinflammation. 7, 3

    Research output: Contribution to journalArticle

    Open Access
    1 Scopus citations

    Prolonged complete response with combined dabrafenib and trametinib after BRAF inhibitor failure in BRAF-mutant glioblastoma

    Kushnirsky, M., Feun, L. G., Gultekin, S. H. & De La Fuente, M. I., 2020, In : JCO Precision Oncology. 4, p. 44-50 7 p.

    Research output: Contribution to journalArticle

    Resection versus biopsy in the treatment of multifocal glioblastoma: a weighted survival analysis

    Di, L., Heath, R. N., Shah, A. H., Sanjurjo, A. D., Eichberg, D. G., Luther, E. M., de la Fuente, M. I., Komotar, R. J. & Ivan, M. E., May 1 2020, In : Journal of neuro-oncology. 148, 1, p. 155-164 10 p.

    Research output: Contribution to journalArticle